FDA reexamines previously rejected rare cancer therapy amid claims of political interference

The FDA has opened a new review of a treatment for a rare form of cancer that it had turned down a few months earlier.

The reconsideration arrives as the agency faces fresh allegations that political pressure from the current administration is influencing its drug approval decisions.

At the same time, the administration is promoting large projected savings from undisclosed drug pricing agreements, though independent analysts say the calculations cannot be independently verified.

Biotech startups are working to deliver oncology care through virtual platforms, and scientists are investigating the “dark proteome,” a previously hidden area of protein biology that could open new therapeutic avenues.